%20(350%20x%20150%20px)%20(90%20x%2040%20px)%20(400%20x%20120%20px)%20(1).png?alt=media&token=d89125a8-b0fb-48cf-b1cc-8bc3bdb4e3a4)
Targeted Cancer Screening
Germline HRR Panel
$699
This test analyzes genes involved in the Homologous Recombination Repair (HRR) pathway. Mutations in these genes can increase the risk for prostate, ovarian, breast, and pancreatic cancers.
Informing Treatment and Risk
Identifying a germline HRR mutation can be critical for guiding treatment decisions, particularly for PARP inhibitor therapies, and for assessing personal and familial cancer risk.
- Targeted Therapy Guidance: Provides key information for eligibility for specific cancer treatments like PARP inhibitors.
- Risk Assessment: Clarifies the genetic risk for developing HRR-associated cancers.
- Proactive Management: Enables the creation of a surveillance and risk-reduction plan tailored to your genetic profile.
Who Should Consider This Test?
This panel is particularly relevant for individuals diagnosed with or having a strong family history of prostate, ovarian, pancreatic, or breast cancer.
Begin Your Journey
Let's discuss how we can elevate your health and wellness strategy. Experience healthcare as it was meant to be.
Priority Hotline Available
Dubai, United Arab Emirates